Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APV006 safety and immunogenicity in healthy adults
NCT05952596Phase 1Unknown
- Sponsor
- LG Chem
- Start
- Jul 2023
- Primary completion
- Oct 2023
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 1, randomised, double-blind trial of APV006 in diphtheria, Tetanus, pertussis and 3 more (2 arms), sponsored by LG Chem. Primary endpoints: Number of subjects with immediate reactions at 30 minutes, Number of subjects with solicited adverse events at 7 days and 2 more. Status: unknown.
02
Drugs
APV006
03
Conditions
diphtheriaTetanuspertussispoliomyelitishepatitis B (HBV)
Beyond the preview
Go deeper on NCT05952596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05952596.